agranulocytosis in Jewish patients with schizophrenia’.
Arch.Gen.Psychiatry 47 : 945–948.
Lin KM, Lesser JM, Poland RE. 1986. ‘Ethnicity and
psychopharmacology culture’.Med. Psychiatry 10 :
151–165.
Lin KM, Mendoza R, Poland RE,et al., 1991. ‘Phar-
macokinetic and other related factors affecting psy-
chotropic responses in Asians’.Psychopharmacol.
Bull. 27 (4): 427–439.
Metropolitan Life Insurance. 1999. Male, Female,
Height and Weight Tables(www.metlife).
Medawar PB. 1961. ‘Immunological tolerance’.Nature
189 : 14–17.
Mendoza R. 1991. Psychopharmacol. Bull. 27 :
449–460.
Ministry of Health and Welfare Notification 660(June
1985); andNotification of PAB Director General:
Acceptance of Data on Clinical Trials Conducted in
Foreign Countries, Japan (29 June 1987).
Natio C, Yasuhova H. 1993. ‘Retrospective survey of
pharmacokinetics: dosage of 80 drugs approved in
the EC, Japan, and US’. E5 Workshop Reports, ICH-
2, Orlando.
Office of Management and Budget: Directive 15.
http://www.whitechase.gov/omb/fedreg/notice_15.html.
Oster G, Huse DM, Deles TE,et al., 1987. ‘Cost-
effectiveness of labetalol and propranolol in the
treatment of hypertension among Blacks’.J. Natl.
Med. Assoc. 79 : 1049–1055.
Pemberton J. 1989. ‘Does constitutional hypotension
exist?’.Br. Med. J. 298 : 660–662.
Papaluca M. 1993. ‘Ethnic factors and clinical respon-
siveness: basic concepts of the retrospective survey’.
ES Workshop Report, ICH-2, Orlando.
Payer L. 1988.Medicine and Culture.H. Holt: New
York.
Rieder MJ, Sheer NH, Kanee A,et al., 1991. ‘Promi-
nence of slow acetylator phenotype among patients
with sulfonamide hypersensitivity reactions’.
J. Clin. Pharm. Ther. 49 : 13–17.
Salzman C. 1982. ‘Increased receptor sensitivity,
psychoactive drugs, and analgesics. A prime of
geriatric psychopharmacology’.Am. J. Psychiatry
139 : 67–74.
Sleath B, Svarstad B, Rotes D. 1998. ‘Patient race and
psychotropic prescribing during medical encoun-
ters’.Patient Educ. Counsel. 34 (3): 227–258.
Strickland TL, Lin KM, Mendoza R,et al., 1991.
‘Psychopharmacologic considerations in the
treatment of Black American populations’.Psycho-
pharmacol. Bull. 27 (4): 441–448.
Takahashi R. 1979. ‘Lithium treatment in affective
disorders: therapeutic plasma level’.Psychopharma-
col. Bull. 15 : 32–35.
US Bureau of the Census. 1991.Press release C891–
100.
US Food and Drug Administration. 2004.ES-Ethnic
Factors in the Acceptability of Foreign Clinical
Data – Questions and Answers (www.fda.gov/
cber/gdlns/iche5ethnic.htm).
Uchida K. 1988. ‘Acceptability of foreign clinical trial
data in Japan’.Drug Inf. J. 22 : 103–108.
Vessell E. 1989. ‘Ethnic differences in reactions to
drugs and xenobiotics’.Prog. Clin. Biol. Res. 214 :
21–37.
Weintraub M, Rubio A. 1992. ‘Scoring system in a
pilot effectiveness study of patients with sickle
cell anemia’.J. Clin. Res. Pharmacoepidemiol. 6 :
47–54.
Wood AJJ, Koshakji RP, Silberstein DJ. 1989. ‘Racial
differences in drug response-altered sensitivity
to and clearance of propranolol in men of Chinese
descent as compared with American Whites’.
N. Engl. J. Med. 320 : 565–570.
Wood AJJ, Zhou HH. 1991. ‘Ethnic differences in drug
disposition and responsiveness’.N. Engl. J. Med.
320 : 565–570;Clin. Pharmacokinet. 20 : 350–373.
World Health Organization. 1990.World Population
Prospects.United Nations Publications: New York.
Yang YY. 1987. ‘Prophylactic efficacy of lithium and its
effective plasma levels in Chinese bipolar patients’.
Acta Psychiatr. Scand. 71 : 171–175.
Zhang Y, Bertilsson L, Lou T,et al., 1990. ‘Diazepam
metabolism in native Chinese, poor and extensive
hydroxylators ofS-mephenytoin: inter-ethnic differ-
ences in comparison with White subjects’.Clin.
Pharmacol. Ther. 48 : 496–502.
Zhou HH, Adeloyin A, Wilkinson GR. 1990. ‘Differ-
ences in plasma-binding of drugs between cauca-
sians and Chinese subjects’.Clin. Pharmacol. Ther.
489 : 10–17.
Zola IK. 1972. ‘Studying the decision to see a doctor’.
InAdvances in Psychosomatic Medicine, vol. 8,
Lipowski Z (ed.). Karger: Basel; 216–236.REFERENCES 247